Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

611
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
611
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

582
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
582
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

628
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
628
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

721
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
721
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

805
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

808
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
808

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An artificial intelligence model to detect abnormal ejection fraction from non-contrast chest computed tomography: the CT-LVEF study.

European heart journal. Digital health·2026
Same author

The novelty of anticoagulation in LVAD Therapy: Current Practice, the Role of Direct Oral Anticoagulants, and Future Directions.

Journal of cardiovascular pharmacology·2026
Same author

A Two-Threshold dd-cfDNA Algorithm Improves Detection of Molecular Rejection in Heart Transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

De Novo Aortic Insufficiency and Its Progression in Patients on Microaxial Flow Pump Support Before Durable Left Ventricular Assist Device.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

The Pendulum Swings: Reconsidering Durable Left Ventricular Assist Devices as a Bridge to Transplantation.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Does Pacemaker Mode Affect Outcomes in Patients With HeartMate 3 LVAD?

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Machine Learning Prediction of Pediatric In-Hospital Survival Before Extracorporeal Membrane Oxygenation Cannulation.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Erratum: Safety and Efficacy of Stored Wet-Preprimed Extracorporeal Membrane Oxygenation Circuits: A Scoping Review.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Case Series of Extracorporeal Cardiopulmonary Resuscitation for Refractory Cardiopulmonary Arrest After Cardiac Surgery.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Association Between Veno-Venous Extracorporeal Membrane Oxygenation and Right Ventricular Dysfunction in Acute Respiratory Distress Syndrome Patients: A Multicenter Retrospective Propensity-Matched Study.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Prolonged Mechanical Circulatory Support of Neonatal Biventricular Failure via Single Ventricle Conversion With Ventricular Assist Device.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

Redefining Limits: Extracorporeal Cardiopulmonary Resuscitation in Adult Thrombotic Thrombocytopenic Purpura.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Left ventricular assist devices improve functional class without normalizing peak oxygen consumption.

Casey R Benton1, Gabriel Sayer, Ajith P Nair

  • 1From the *Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 10029; †Division of Cardiology, University of Chicago Medical Center, Chicago, Illinois 60637; ‡Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029; and §Department of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York 10029.

ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|January 31, 2015
PubMed
Summary
This summary is machine-generated.

Left ventricular assist device (LVAD) support improves heart failure patients' functional capacity. Peak oxygen consumption (VO2 max) increases significantly after LVAD implantation but does not reach predicted normal levels.

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Related Experiment Videos

Last Updated: Apr 18, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Area of Science:

  • Cardiology
  • Medical Devices
  • Exercise Physiology

Background:

  • Heart failure significantly impairs functional capacity and quality of life.
  • Left ventricular assist devices (LVADs) are used to support patients with advanced heart failure.
  • Improvements in functional capacity after LVAD implantation are expected to correlate with objective measures of exercise performance.

Purpose of the Study:

  • To evaluate the impact of HeartMate II LVAD support on peak oxygen consumption (VO2 max) as measured by cardiopulmonary exercise testing (CPET).
  • To determine if VO2 max normalizes to predicted values post-LVAD implantation despite functional class improvements.
  • To assess the relationship between pre-implantation heart failure severity and the degree of VO2 max improvement.

Main Methods:

  • Retrospective review of HeartMate II LVAD recipients who underwent CPET.
  • Analysis of CPET data, including VO2 max, before and after LVAD implantation.
  • Comparison of post-implant VO2 max with predicted values and pre-implant measurements.

Main Results:

  • 37 patients completed CPET post-LVAD implantation; 10 had pre-implant data.
  • 91.4% of patients improved by at least two NYHA functional classes.
  • Post-implant VO2 max was significantly lower than predicted (51% ± 12%), but increased significantly from pre- to post-implantation (11.6 ± 5.0 to 15.4 ± 3.9 ml/kg/min, p = 0.009).

Conclusions:

  • LVAD support significantly improves VO2 max in heart failure patients.
  • Despite functional class improvements, VO2 max does not normalize to predicted levels after LVAD implantation.
  • Pre-implantation heart failure severity did not correlate with the extent of VO2 max improvement.